

## Minutes of the 2026 Annual General Meeting of Shareholders

### Mega Lifesciences Public Company Limited

#### Date, Time and Venue

This meeting was held on 3 April 2026 at 2:00 p.m. via electronic media (e-AGM) only pursuant to the Emergency Decree on Electronic Meeting B.E. 2563 (2020), including other relevant laws and regulations, broadcasted live at a meeting room of Mega Lifesciences Public Company Limited (the “Company”) at 20<sup>th</sup>, No. 909 Ample Tower, Debaratna Road, Bangna Nuea Sub-district, Bangna District, Bangkok 10260. The meeting was recorded as a video media.

#### Start of the Meeting

Ms. Tananya Pipitwanitchakan, the master of ceremony (the “MC”), welcomed the shareholders to the 2026 Annual General Meeting of Shareholders of the Company (the “Meeting”) and introduced to the Meeting the directors, where 10 of them (i.e., 91% of all directors) attended the Meeting, with three directors presented in the meeting room and seven directors attending the Meeting remotely via electronic media. One director was unable to attend the meeting due to other commitments. The MC then introduced to the Meeting the auditors, advisors, corporate secretaries and the Company that handled the vote counting. The MC also informed the Meeting that there were 20 shareholders presented at the Meeting with combined shares of 920,381 shares, and there were 301 proxies with 654,553,701 shares. This equated to the total of 321 shareholders with 655,474,082 shares, equivalent to 75.1803 percent of the 871,869,508 total issued shares of the Company, which constituted the quorum pursuant to the laws and the Articles of Association of the Company.

The MC then informed the Meeting that the Company provided translation devices for foreign shareholders and that the Company arranged the invitation to the Meeting and informed the shareholders regarding this Meeting via three methods: (i) the Company had delivered the invitation notice to the Meeting to all shareholders by registered mail, (ii) the Company had published the invitation to the Meeting on newspapers and (iii) the Company had announced details of the Meeting on the Company’s website 30 days prior to the Meeting. The MC then notified the Meeting of the procedures of the Meeting, the rules on voting and the details of each agenda.

#### Directors present at the Meeting (91 percent)

1. Mr. Alan Kam	Chairman of Board of Directors and Independent Director
2. Dr. Nithinart Sinthudeacha	Vice-Chair of Board of Directors, Independent Director, Chair of Sustainability, Risk Management and Corporate Governance Committee
3. Mr. Vijay Karwal	Independent Director, Member of Audit Committee, and Chair of Nomination Committee
4. Mr. Thor Santisiri	Independent Director, Chair of Remuneration Committee and Member of the Audit Committee
5. Mr. Kirit Shah	Non-Executive Director and Member of Remuneration Committee
6. Ms. Sameera Shah	Non-Executive Director
7. Mr. Shiraz Erach Poonevala	Non-Executive Director
8. Mr. Ramchandran Rajamanickam	Independent Director
9. Mr. Vivek Dhawan	Executive Director, Chief Executive Officer, Member of Remuneration Committee, and Member of Sustainability, Risk Management and Corporate Governance Committee

10. Mr. Thomas Abraham

Executive Director, Chief Financial Officer and Member of Sustainability, Risk Management and Corporate Governance Committee

**Director(s) not present at the Meeting**

1. Mr. Ishaan Shah

Non-Executive Director

**Advisors present at the Meeting**

**Auditor**

KPMG Phoomchai Audit Ltd.

Ms. Sureerat Thongarunsang

Mr. Nicholas Bellamy

Mr. Thanathep Lerkittiphan

Mr. Weeraphat Pangsorn

**Legal Advisor**

Hunton Andrews Kurth (Thailand) Limited

Ms. Wichaya Apiratkasem

Ms. Supajit Koosittiphon

**Company Secretary, Deputy Director of Management and Finance and Vote Counters**

**Company Secretary**

Ms. Sujintana Boonworapat (“Ms. Sujintana”)

**Deputy Chief Financial Officer**

Mr. Manoj Gurbuxani

**Senior Vice President of Finance**

Mr. Francis Rego

**Vote Counting Company**

OJ International Co., Ltd.

Before the Chairman of Board of Directors declared the 2026 Annual General Meeting of Shareholders of the Company to be duly convened, the MC explained procedures for the Meeting, voting procedures and details on each meeting agenda as follows:

1. To vote in each agenda, voters would have as many votes as the number of shares he held or the number of shares he had proxy. One share would be equal to one vote and no vote shall be divisible, except, he is a proxy holding Proxy Form C as a custodian of foreigner investors.

The proxies holding Proxy Form B which the proxy grantor has specified the voting in the proxy form must cast their votes as directed by the proxy grantor, in one of the following manners, i.e. approve, disapprove or abstain.

2. The officer will share a link to vote only to:
  - (1) the shareholders attending the meeting in person;
  - (2) the proxies appointed by using Proxy Form A; and
  - (3) the proxies appointed by using Proxy Form B and Form C in case the grantor has specified in the proxy form that the proxy shall have the right on his/her behalf to consider and approve independently as the proxy deems appropriate.

In the case the grantors already specified the voting in the proxy forms and appointed the proxies to exercise such specified votes, the officer will record the votes as specified in the proxy forms when the proxies register for the meeting attendance.

3. Before casting the votes in each agenda, the opportunity will be given to the meeting attendees to inquire on the issues related to such agenda as appropriate, where the window for such inquiry will be one minute. In this regard, the meeting attendee who wishes to inquire, please notify the position as a shareholder or proxy to the Meeting for purposes of recording the minutes of the meeting.

For method of inquiry, meeting attendees can inquire via two following channels:

Channel 1: Inquiry via messages: Meeting attendees can send messages by clicking on Q&A button on Zoom, to type and enter inquiries to the system;

Channel 2: Inquiry via video/ audio conference: Meeting attendees can raise hand by clicking on Raise Hand button and wait until the system operator open the microphone in the system for you. When the microphone is opened for you, please click Unmute button and then raise your inquiries.

4. In counting the votes for each agenda, the Company will use the method of deducting the disapproved votes and abstained votes from all of the votes. The remaining votes will be deemed as the approved votes. As the meeting is conducted via electronic media only, there will be no voting ballots printed for meeting attendees. The Company shall count the votes from the e-Voting system, which will be opened for voting with a 1-minute window to vote for each agenda. When voting, meeting attendees must switch from Zoom to main menu in the browser used to log in to the meeting, and click on e-Voting button to vote within the specified 1-minute window, after clicking on the voting option, the system will pop-up a box requesting confirmation on the vote. The meeting attendees must press agree to confirm the vote. In case the shareholders wish to change the voting, they can do so by clicking on the new vote again. Once the agenda has been closed, shareholders will not be able to vote or change their voting. When you have finished voting, please return to Zoom to continue watching the video of the meeting.
5. In case that some shareholders or proxies would like to leave the meeting early, please go to e-Voting and vote on the remaining agenda(s) before you leave. For the accurated vote counting, the officers will record your votes in to each agenda.
6. The votes counting will be conducted immediately after the Chairman has requested the shareholders to approve in each agenda. The total votes counted would be a result of votes exercised by shareholders attending the meeting themselves and those attending it by proxy. The votes counting will be displayed on Zoom window.

In case of the tied votes, the Chairman of the Meeting shall have an additional vote as the casting vote.

7. The resolution in each agenda will be as the following:

Agenda Item Nos. 1, and 2 are for acknowledgement and no casting of vote

Agenda Items Nos. 3, 4, 5 and 7 must be approved by a majority of the shareholders who attend the Meeting and cast their votes, excluding the abstained votes from the calculation base.

Agenda Item No. 6 must be approved by a vote of not less than two-thirds of the shareholders who attend the Meeting, including the abstained votes in the calculation base.

Mr. Alan Kam, the Chairman of the Board of Directors, acted as the Chairman of the Meeting (the "Chairman"). The Chairman declared the 2026 Annual General Meeting of Shareholders of the Company to be duly convened and started the Meeting as follows.

**Agenda Item No. 1      Message from the Chairman and Chief Executive Officer to the Meeting**

The Chairman welcomed the shareholders to the 2026 Annual General Meeting of Shareholders and informed the Meeting initially that this year has been another challenging year for the Company due to the global economic conditions and the slowdown in international trade. Nevertheless, the Company has remained strong, with a continued focus on its core business and a solid cash flow position. In addition, the Company offered high-quality products at accessible price points and maintained

ongoing research and development (R&D) efforts to support long-term growth over the next 5 – 10 years.

Despite the slowdown in expansion into the European and East Asian markets over the past two to three years due to economic conditions, the Company remained confident in its ability to continue operating sustainably. With a workforce of over 5,400 employees dedicated to their work, the Company continued to build knowledge and capabilities to ensure long-term, stable growth. Furthermore, the Company's management team possessed a strong vision in driving the organization towards a high-quality and sustainable business.

The Company's business would be presented by Mr. Vivek Dhawan, Chief Executive Officer (CEO) and Chief Coach of the Company ("Mr. Vivek").

Mr. Vivek thanked the Chairman, the directors and every shareholders for attending the Meeting and informed the Meeting as follows.

Mr. Vivek expressed his appreciation to Mr. Mechai Viravaidya, the former Chairman of the Board of Directors, who had worked closely with the Company for over 10 years, including the period prior to the Company's listing on the Stock Exchange, and who had played a significant role in fostering a positive mindset within the organization.

With respect to concerns regarding the war situation in Iran and issues in Myanmar, the Company clarified that the impact on its operations was not so significant. This was because the Company's reliance on oil was relatively low, and the Company could still export its products without significant disruption. Approximately 75 – 76% of the Company's business was based in Asia, with the rest in the United States and Africa.

Over the past 12 years since the Company's listing on the Stock Exchange in 2013, the Company has demonstrated consistent profit growth. From an initial profit of approximately Baht 500 million, the Company managed to double its profit to over Baht one billion during the period from 2013 to 2019. In 2025, the Company achieved a profit of approximately Baht 1.9 billion, which was close to its target, resulting in the Company having doubled its profits twice over the 12-year period.

Looking ahead, the Company has established its "Road to 2030" strategy, which includes a five-year in-depth plan for "MEGA We care" brand expansion across 33 countries and to strengthen brand recognition in all markets where the Company operated. The Company aimed to increase annual sales from approximately USD 300 million to USD 500 million within five years and to achieve profits of Baht 3.5 billion by 2030. To achieve these goals, the Company would focus on two key segments: (i) pharmaceutical products distributed through hospitals and clinics, and (ii) An anti-allergy drug, a new products currently undergoing registration in various countries, with approximately 120 products in the pipeline.

In addition, the Company continued to focus on its Human Health Care business, which included products for common conditions such as vitamins and other consumer healthcare products. These products were distributed across several markets, including Peru, Colombia, Ukraine, and Uzbekistan. The Company also held leading positions in various markets with products such as NAT B, NAT C, Omega 3, and Gofen.

With respect to investments, the Company has continued to expand its business operations across several countries, as detailed below:

1. As previously disclosed to shareholders approximately three years ago, the Company acquired a manufacturing facility in Indonesia and has since made additional investments to expand its production capacity. The construction and expansion of the facility were now nearing completion. The Company expected to commence production at this facility within the third quarter of this year. The plant would primarily serve the Indonesian market, which had strong growth potential.

2. The Company has commenced the construction of a pharmaceutical manufacturing facility in Vietnam, located near Ho Chi Minh City. This investment has been driven by Vietnam's policies and regulations that promoted domestic production, as well as the Company's long-standing presence in the Vietnamese market for over 30 years, which has enabled it to develop strong market knowledge and a solid customer base. The pharmaceutical market in Vietnam was currently valued at approximately USD five billion and was projected to grow to approximately USD seven to eight billion over the next 5 – 10 years. Accordingly, the Company saw significant opportunities to expand its business both in terms of domestic production and export to international markets. The construction of the facility and the process of obtaining the necessary regulatory approvals were expected to take no less than two years. The Company anticipated to commence sales of products manufactured at this facility around the second quarter of 2029.
3. The Company has also received approval from its Board of Directors to invest in Myanmar, where it has operated for over 30 years. The investment aimed to establish a pharmaceutical manufacturing facility to support domestic production and distribution. The project was currently in the design phase, and the Company also expected to commence production at this facility around the third quarter of 2029.

The Company remained confident that these investments and business expansions would enhance its competitive capabilities and support the achievement of its long-term business objectives.

In terms of sustainability, the Company placed significant emphasis on environmental responsibility. The Company has invested approximately USD 2.5 million in installing solar energy systems at its manufacturing facilities, which helped reduce carbon dioxide emissions by approximately 1,400 tons per year. The Company also continued to make environmental investments in other countries where it operated.

In addition, the Company has invested in a health center (Wellness WeCare Center) in Thailand, located in Muak Lek District, Saraburi Province, to promote health awareness among the public, including healthcare professionals. The Company was also a member of the Collective Action Against Corruption (CAC) and has received a high corporate governance (CG) rating. The company continuously complies with regulations to maintain good corporate governance standards.

Further, the MC provided an opportunity for the Meeting to provide any opinions and queries in relation to this agenda. In this regard, the shareholder(s) provided the opinion(s) and enquired the query(ies) as follows:

**Opinion/ Query/ Response:**

**Dr. Jomkwan Supasirikitjaroen**, a shareholder attending the Meeting in person, inquired about how the Company viewed the growing aging population as a business opportunity and which of the Company's product categories were best positioned to meet the needs of this demographic.

**Mr. Vivek** clarified that the majority of the Company's products were designed to meet the needs of the aging population, particularly those related to the prevention and management of age-related conditions such as cardiovascular diseases and hypertension. These products primarily focused on promoting and supporting overall health and well-being.

In addition, the Company has been operating health centers to enhance public awareness of health and wellness, including providing education on proper sleep, balanced nutrition, and comprehensive health care practices.

Remark: This agenda was for acknowledgement. Therefore, there was no casting of votes.

**Agenda Item No. 2**

**To acknowledge the report on the result of the Company's and its subsidiaries' business operations for the year ended December 31, 2025**

The MC informed the Meeting that the Company had prepared the Form 56-1 One Report 2025 (Annual Report) and sent to the shareholders in the form of QR Code together with the notice of this Meeting and posted on the Company's website (www.megawecare.com).

In this regard, the Board deemed appropriate to propose the Meeting to acknowledge the report on the result of the Company's and its subsidiaries' business operations for the year ended December 31, 2025.

Further, the MC provided an opportunity for the Meeting to provide any opinion and enquire any queries in relation to this agenda. In this regard, the shareholder(s) provided the opinion(s) and enquired the query(ies) as follows:

**Opinion/ Query/ Response:**

**Ms. Katarat Sribenjukul**, a proxy of the Thai Investors Association, inquired through the question submission channel on the Management Discussion and Analysis on the operation results of the fourth quarter of 2025 on the sign of revenue recovery in Myanmar as a result of business model adjustment to dual currency model, and asked the Company to clarify how such dual currency had helped mitigate risk from the enforcement of Proof of Export rule by the government of Myanmar, and on whether the recovered revenue was from actual sales or from accounting adjustment due to currency conversion.

**Ms. Sujintana** clarified that the effect of the dual currency model and the revenue recovery in Myanmar were two different subjects. The effect of the dual currency model was from difference in the currency exchange rate used in actual market for transactions and the currency exchange rate determined by central bank. In preparing its financial statements, the Company used the official rate. However, in the Management Discussion and Analysis, the Company adjusted the number to properly reflect the market rate so that the information can be used to compare and reflect the actual performance more accurately. Both cases did not materially impact the Company's ability to generate profits. On the revenue in Myanmar, the Company had started notice the positive sign since the third quarter of 2025, and the Company already disclosed the same in its Management Discussion and Analysis.

**Ms. Katarat Sribenjukul**, a proxy of the Thai Investors Association, inquired through the question submission channel on the Company's progress in applying for new investment promotion from the Board of Investment of Thailand (the "BOI") for its factories in Thailand after exhaustion of the BOI tax benefits, including the Company's other plans to manage the increased tax burden.

**Ms. Sujintana** clarified that the Company already exhausted its BOI tax benefits in December 2024, and the current effective rate of tax was at 21% which was considered normal compared to other companies operating businesses in Southeast Asia and Africa. At present, the Company was considering new investment projects focusing on expanding its manufacturing capacity and enhancing its operation efficiency. If any of such projects was qualified for investment promotion from the BOI, the Company would then apply for the investment promotion for such project.

**Ms. Katarat Sribenjukul**, a proxy of the Thai Investors Association, inquired through the question submission channel on the effect of Mayuree Naree vessel incident (i.e., the vessel being attached while transiting through the Strait of Hormuz) in March 2026 towards the Company, particularly, on whether and how much the Company suffered

any freightage cost and war risk insurance cost for importing raw materials from Europe, and on the Company's contingency plan in a case of long-term cessation of international transport routes.

Mr. Vivek clarified that such Mayuree Naree vessel incident was unlikely to affect the Company's operations, given that the Company imported raw materials from many countries, i.e., countries in Europe, and also China and India. At present, the Company was still able to import raw materials as usual. For export, there was no actual effect either due to that around 60 – 80% of the Company's export activities were in Asia, and the export activities in Africa could also be carried out as usual.

**Remark:** This agenda was for acknowledgment. Therefore, there was no casting of votes.

**Agenda Item No. 3 To consider and approve the statements of financial position and profit and loss statements of the Company for the year ended December 31, 2025**

According to Section 112 of Public Limited Company Act B.E. 2535 (1992) (as amended) (the "PLCA") and Articles 39 and 40 of the Company's Articles of Association, a public company is required to prepare an audited statement of financial position and profit and loss statement for submission to the shareholders' meeting for consideration and approval.

Ms. Sujintana summarized material items of the statement of financial position and profit and loss statements of the Company for the year ended December 31, 2025, as audited by KPMG Phoomchai Audit Ltd., the Company's auditor, reviewed by the Audit Committee and approved by the Board to the Meeting as follows:

(Unit: Million Baht)

Description	Consolidated Financial Statements		Company's Financial Statements	
	2025	2024	2025	2024
Total assets	15,759.2	14,210.1	8,519.6	8,277.8
Total liabilities	5,544.0	4,333.3	1,224.3	1,017.4
Total equity	10,215.2	9,876.8	7,295.3	7,260.5
Total revenue	14,278.2	15,447.0	5,521.1	5,762.0
Net profit for the year	1,912.0	2,012.6	1,422.8	1,972.7
Net profit attributable to:				
Owners	1,912.0	2,012.5	1,422.8	1,972.7
Non-controlling interests	(0.0)	0.1	-	0.0
Issued & paid-up capital	435.9	435.9	435.9	435.9

Description	Consolidated Financial Statements		Company's Financial Statements	
	2025	2024	2025	2024
Ordinary shares (No. of share)	871.9	871.9	871.9	871.9
Earnings per share (Thai Baht)	2.19	2.31	1.63	2.26

In 2025, the Company had:

- total assets of 15,759.2 million Baht;
- total liabilities of 5,544.0 million Baht;
- total equity of 10,215.2 million Baht;
- total revenue of 14,278.2 million Baht;
- net profit of 1,912.0 million Baht; and
- earnings per share of 2.19 Baht per share.

In this regard, the Board deemed appropriate to propose the Meeting to consider and approve the statements of financial position and profit and loss statements of the Company for the year ended December 31, 2025, as audited by KPMG Phoomchai Audit Ltd., reviewed by the Audit Committee, and approved by the Board.

Further, the MC provided an opportunity for the Meeting to provide any opinion and enquire any queries in relation to this agenda. In this regard, the shareholder(s) provided the opinion(s) and enquired the query(ies) as follows:

**Opinion/ Query/ Response:**

**Mr. Anukul Piyathananukul**, a shareholder attending the Meeting in person, inquired through the question submission channel on remark 4 of the financial statements regarding related companies (page 324 of One Report) on loan to and outstanding interests from subsidiaries, where an amount of roughly Baht 315 million had been recorded as impairment loss. Such amount was almost equivalent to the total loan amount, and the same applied to 2024. What caused such impairment loss, and why the Company kept lending to its subsidiaries in the past two years.

**Ms. Sujintana** clarified that the loan amount was the loan to the Company's subsidiaries. The subsidiaries had suffered loss and as such the Company decided to set impairment loss in an amount of 100% for both the principal amount and interests, as reflected in the Company's financial statements. To clarify, the intercompany transactions were not shown on the consolidated financial statements.

**Mr. Anukul Piyathananukul**, a shareholder attending the Meeting in person, inquired through the question submission channel on the information on page 383 of One Report regarding contingent liabilities with financial institutions to guarantee the Company's subsidiaries in respect of line of credit use in 2025 which were quite high (i.e., as at 31 December 2025: Baht 2,342 million, USD 66 million, IDR 28 billion and MMK 10 billion), on the likelihood of such amounts becoming actual liabilities in the future and the risk of the Company having to pay for them.

**Ms. Sujintana** clarified that such contingent liabilities was a credit line limit for the entire group of the Company, which had only been partly utilized, with the details as appeared in current liabilities on page 296 of One Report. There would be no risk as in the future the Company would still be able to paid as usual.

**Mr. Anukul Piyathananukul**, a shareholder attending the Meeting in person, inquired through the question submission channel on whether the amount of Baht 315.9 million of loss from impairment of loans could be used as tax incentives, or whether it was non-deductible expense.

**Ms. Sujintana** clarified that the Company already set impairment loss in an amount of 100% as appeared in the financial statements of the subsidiary. Such amount could be accumulated for five years but could not be used as tax incentives.

**Mr. Anukul Piyathananukul**, a shareholder attending the Meeting in person, inquired through the question submission channel on the Company's policy in adjusting the price of its products to reflect the actual costs, in a case where the production costs significantly increased (e.g., by 30 – 50%) following market trends, especially in key markets such as Myanmar, Vietnam and Indonesia, to protect the sales and market shares.

**Mr. Vivek** clarified that there were many factors to consider when it came to price adjustment, cost of raw materials was one of them. The Company may purchase more raw materials when their prices decrease, which was one of the Company's marketing strategy. At present, given the price of gasoline, there should not be more than 1 – 2% of impact. The Company had already entered into contracts to procure raw materials/goods for the next six months, and as such the Company did not currently have any plan to adjust the price. Nevertheless, the Company would continue to monitor the market situation.

**Ms. Chonticha Ngerbumrung**, a shareholder attending the Meeting in person, inquired through the question submission channel on whether the Company has changed or increased its investment budget for construction of factories and warehouses in foreign countries after the increase in energy cost.

**Mr. Vivek** clarified that the Company did not have any plan to adjust or increase the said budget. In this respect, the Company would continue to invest in constructing the factories and warehouses in foreign countries, in line with the Company's long-term business plan and the Company's business nature (i.e., being medicine business which was a long-term business requiring time in building, starting from product manufacturing, registration and sale). For example, Indonesia imposed restrictions on pharmaceutical imports, requiring products to be manufactured domestically. Vietnam was more likely to support domestically manufactured products. The Company had been successful in Vietnam market and would like to continue expanding its business in Vietnam. The same applied to Myanmar, although there were also restrictions on pharmaceutical imports, the Company's products had been well known and well-credited in Myanmar market. It was thus a good opportunity for the Company to expand its market in Myanmar through investing in constructing its factory to manufacture and sell the products in Myanmar. The Company also planned to also export certain products manufactured in Myanmar.

**Ms. Chonticha Ngerbumrung**, a shareholder attending the Meeting in person, inquired through the question submission channel on packaging fee as to how much such fee accounted for the cost, and the Company's plan to deal with worst-case scenario.

**Mr. Vivek** clarified that the effect from currency value and increased gasoline price would not be over 1 – 2%, and packaging fee accounted for only around 3% of the cost. As such, if the package fee increased by 10 – 20%, such increase would impact the cost only around 0.5 – 0.6%. In addition, the Company still had products in-stock

for sale in the next three to four months. Accordingly, there should not be any significant impact. Nevertheless, the Company would continue to monitor the scenario.

Once there was no further enquiry or opinion, the MC then asked the Meeting to consider and approve the statements of financial position and profit and loss statements of the Company for the year ended December 31, 2025, as proposed above and cast the votes in this agenda via e-Voting system.

**Resolution:** The Meeting considered and resolved to approve the statement of financial position and profit and loss statements of the Company for the year ended December 31, 2025, as proposed with the following voting results:

Shareholders voting	Numbers of Votes	Accounting for percent
Approve	655,525,292	100.0000
Disapprove	0	0.0000
Voided	0	0.0000
Total (327 persons)	655,525,292	100.0000
Abstain	0	-

**Remark:** This agenda was to be approved by a majority of the shareholders who attend the meeting and cast their votes, excluding the abstained votes from the calculation base.

**Agenda Item No. 4**

**To acknowledge the interim dividend paid during year 2025 and to consider and approve the allocation of profit and payment of final dividend of Baht 0.80 per share according to the operation results in the year ended December 31, 2025**

According to Section 116 of the PLCA and Article 45 of the Articles of Association of the Company, the Company is required to set aside as a legal reserve at least 5% of its net earnings in that particular year after deducting retained loss brought forward (if any) until such legal reserve reaches 10% of the registered capital. The legal reserve of the Company had already reached 10% of the registered capital as required by the PLCA and Articles of Association of the Company.

For the interim dividend paid during the year 2025, pursuant to Section 115 of the PLCA and Article 44 of the Articles of Association of the Company, the Board may pay interim dividend to the shareholders from time to time if the Company has profit to justify such payment; after the interim dividend have been paid, the matter shall be reported to the shareholders at the next meeting. The Meeting was therefore proposed to acknowledge the payment of the interim dividend already paid in 2025 in the total amount of Baht 697.50 million which had already been paid on a base of 871,869,508 shares at Baht 0.80 per share. Such dividend had been paid from accumulated profit and operation results of the Company for the fiscal period ended June 30, 2025. The Company paid the interim dividend to the shareholders on September 12, 2025 (the "Interim Dividend").

Dividend Payment Policy

The Company had a policy to pay dividends in the amount of not less than 25% of the annual net profit after deduction of corporate income tax and appropriation of statutory reserves as stated in the Articles of Association of the Company and related laws. However, the dividend payment for each year may vary depending on the business operations, financial condition, investment plan and the need for working capital for business operations and expansion as well as other relevant factors.

Allocation of Profit for Final Dividend Payment

The operating results for the fiscal year ended December 31, 2025 showed that the Company had net income after corporate income tax (financial statements on a standalone basis) in the amount of Baht 1,422.80 million and net profit after corporate income tax (financial statements on a consolidated basis) in the amount of Baht 1,912.0 million. The legal reserve of the Company had already reached 10% of the registered capital as required by the PLCA and Articles of Association of the Company. Thus, the Company deemed it appropriate to pay the dividend for the fiscal year ended December 31, 2025 to the shareholders in the total amount of not exceeding Baht 1,395.0 million or equivalent to 98.0% of the annual net profit after corporate income tax (financial statements on a standalone basis) and 73.0% of the annual net profit after corporate income tax (financial statements on a consolidated basis) which was in line with the dividend payment policy of the Company at the rate of not less than 25% of the net profit of the Company.

As the Company had paid the Interim Dividend of Baht 697.50 million to the shareholders during the year 2025, the Company would pay the rest of the dividend for the year ended December 31, 2025 in the amount of not exceeding Baht 697.50 million.

Therefore, the Company shall pay the dividend from the accumulated profits and operation results for the fiscal year ended December 31, 2025 in the remaining amount up to Baht 697.50 million, which would be paid to shareholders on a base of 871,869,508 shares at Baht 0.80 per share (eighty satang per share) (the "Final Dividend"). In this regard, 75% of the Final Dividend would be paid from Company's net profit for year ending December 31, 2025 and retained earnings as at December 31, 2024 subject to 20% corporate income tax. The remaining 25% of the Final Dividend would be paid from the Company's net profit for year ending 31 December, 2025 and retained earnings as at December 31, 2024 from tax exempt income.

Therefore, the Final Dividend to be paid from net profits and retained earnings derived from income subject to 20% corporate income tax amounts to Baht 523.1 million and the Final Dividend to be paid from net profits and retained earnings from tax exempt income would be Baht 174.4 million pursuant to the following details:

- The Final Dividend of Baht 0.60 per share, paid from the net profits and retained earnings with 20% corporate income tax, the shareholder would be subject to a withholding tax of 10% and entitled to a tax credit at the rate of 20/80 of the dividend.
- The Final Dividend of Baht 0.20 per share paid from net profits and retained earnings from tax exempt income, the shareholder would be subject to a withholding tax of 10% and not entitled to a tax credit.

Dividend details	Year 2025			Year 2024		
	No. of Shares	Dividend per share (Baht)	Total (Baht)	No. of Shares	Dividend per share (Baht)	Total (Baht)
Interim Dividend	871,869,508	0.80	697,495,606	871,869,508	0.80	697,495,606
Final Dividend	871,869,508	0.80	697,495,606	871,869,508	0.80	697,495,606
<b>Total Dividend</b>	<b>871,869,508</b>	<b>1.60</b>	<b>1,394,991,212</b>	<b>871,869,508</b>	<b>1.60</b>	<b>1,394,991,212</b>

In this regard, the shareholders who were disqualified to receive the dividend under the law would not be entitled to this dividend payment.

Ms. Sujintana summarized the 2025 dividend payment whereby the Company paid the Interim Dividend in the amount of Baht 0.80 per share, totalling Baht 697,495,606 on September 12, 2025 and would request the approval from the Meeting for the allocation of the last phase of Final Dividend payment in the amount of Baht 0.80 per

share, totalling Baht 697,495,606, which would be paid on April 24, 2026. The total dividend was Baht 1.60 per share or equivalent to Baht 1,394,991,212 in total.

In this regard, the Board deemed appropriate to propose to the Meeting to acknowledge the 2025 interim dividend payment for the fiscal year ended December 31, 2025, as mentioned above and deemed appropriate to propose to the Meeting to consider and approve the allocation of the profit from the operation results in the fiscal year ended December 31, 2025 and the retained earnings as of December 31, 2024 to distribute the Final Dividend, as well as the granting of authority to either Mr. Vivek Dhawan, Chief Executive Officer (CEO) and/or Mr. Thomas Abraham, Chief Financial Officer (CFO) to do take such actions necessary for such dividend payment.

Further, the MC provided an opportunity for the Meeting to provide any opinion and enquire any queries in relation to this agenda. However, there were no opinions provided or queries asked. The MC then asked the Meeting to acknowledge the Interim Dividend paid during year 2025 and to consider and approve the allocation of profit and payment of final dividend of Baht 0.80 per share according to the operational results for the fiscal year ended December 31, 2025, as follows:

- (1) to acknowledge the Interim Dividend paid in the total amount of Baht 697.50 million which had already been paid on a base of 871,869,508 shares at Baht 0.80 per share. Such Interim Dividend was paid from accumulated profit and operational results of the Company for the fiscal period ended June 30, 2025. The Company paid the said Interim Dividend to the shareholders on September 12, 2025;
- (2) to approve the allocation of profit and payment of dividend from the operational results for the fiscal year ended December 31, 2025 in the total amount of not exceeding Baht 1,395.0 million or equivalent to 98.0% of the annual net profit after corporate income tax (the financial statements on a standalone basis) and 73.0% of the annual net profit after corporate income tax (financial statements on a consolidated basis) which was in line with the dividend payment policy of the Company at the rate of not less than 25% of the annual net profit after corporate income tax and legal reserve;
- (3) to approve the payment of the Final Dividend according to the operational results in the years ended December 31, 2025 and retained earnings as of December 31, 2024 in the remaining amount up to Baht 697.50 million (total dividend in item (2) less the Interim Dividend of Baht 697.50 million paid in 2025 in item (1)), equivalent to the rate of Baht 0.80 per share, which would be paid to shareholders on a base of 871,869,508 shares to those shareholders whose names appear on the share register book as at the record date for determining the names of shareholders who shall be entitled to receive dividend on March 10, 2026 and set the payment date of the dividend to be April 24, 2026; and
- (4) to authorize either Mr. Vivek Dhawan, CEO and/or Mr. Thomas Abraham, CFO to do all such acts and deeds as may be required to consummate the payment of such dividend as stated above,

and cast the votes in this agenda, via e-Voting system.

**Resolution:** The Meeting considered and acknowledged the interim dividend paid during 2025, approved the allocation of profit for the payment of Final dividend at the rate of Baht 0.80 per share from the operational results for the fiscal year ended December 31, 2025 and approve the payment of the Final Dividend from to the operational results in the years ended December 31, 2025 and retained earnings as of December 31, 2024 to be paid on April 24, 2026, and approved Mr. Vivek Dhawan, CEO and/or Mr. Thomas Abraham, CFO to do all such acts and deeds as may be required to consummate the payment of such dividend as stated above.

Shareholders voting	Numbers of Votes	Accounting for percent
Approve	655,525,302	100.0000
Disapprove	0	0.0000
Voided	0	0.0000
Total (328 persons)	655,525,302	100.0000
Abstain	0	-

Remark: This agenda was to be approved by a majority of the shareholders who attend the meeting and cast their votes, excluding the abstained votes from the calculation base.

**Agenda Item No. 5**

**To consider and approve the election of the Company's directors to replace those who must retire by rotation**

The MC informed the Meeting that according to the Sections 70 and 71 of the PLCA and Articles 16 and 17 of the Articles of Association of the Company, at least one-third of the total number of directors must retire by rotation at the Annual General Meeting of Shareholders in each year, and if the number of directors cannot be divided into three, the closest number to one-third shall retire and the retired directors are eligible for re-election.

The MC informed the Meeting that there would be three directors to be retired by rotation at the Annual General Meeting of Shareholders of the Company for 2026 are as follows:

- (1) Mr. Thor Santisiri an Independent Director, Member of the Audit Committee and Chair of the Remuneration Committee;
- (2) Mr. Kirit Shah a Non-Executive Director, and Member of the Remuneration Committee; and
- (3) Ms. Sameera Shah a Non-Executive Director.

Mr. Thor Santisiri has advised the Board that he does not wish to seek re-election as a director.

The Nomination Committee (exclusive of those with vested interests on this matter) had undertaken the nomination criteria and process by taking into consideration all the required aspects of directors, i.e., qualifications, knowledge, competency, experience and expertise in the best interest of the Company and resolved to propose the appointment of two directors, i.e., Mr. Kirit Shah and Ms. Sameera Shah for another term, and to appoint Mr. Plakom Wanglee as an independent director to replace Mr. Thor Santisiri who does not seek re-election.

Nomination Committee (exclusive of those with vested interests on this matter) had reviewed the qualifications of Mr. Plakom Wanglee and is of the opinion that Mr. Plakom Wanglee, who has passed Nomination Committee screening test and have availability to perform his duties as director of the Company, is knowledgeable, competent, experienced, and skillful in the benefit to the Company's operations and has full qualifications and does not have any prohibited characteristics under the PLCA, the Securities and Exchange Act B.E. 2535 (1992) (as amended) and the relevant regulations. Moreover, to take a position of independent director, Mr. Plakom Wanglee can provide the opinion freely and in accordance with relevant rules and regulations. In addition, the candidate also possesses the qualifications in accordance with the Company's policy, which is in accordance with the requirements of the Office of the Securities and Exchange Commission and the Stock Exchange of Thailand.

In this regard, the Board (exclusive of those with vested interests on this matter) deemed appropriate to propose the Meeting to consider and approve the election of the two retiring directors, i.e., Mr. Kirit Shah and Ms. Sameera Shah for another term, and to consider and approve the appointment of Mr. Plakorn Wanglee as an independent director to replace Mr. Thor Santisiri who does not seek re-election.

In addition, the Company also gave an opportunity for the shareholders to propose the names of the persons to be consider to be appointed as the directors from October 1, 2025 to January 31, 2026 by disclosing through an announcement on the Company's website and the electronic system of the Stock Exchange of Thailand. However, no shareholders proposed other persons for the position.

The MC then asked the Meeting to consider and approve the election of the Company's directors to replace those who must retire by rotation on an individual basis, as proposed above, and cast the votes in this agenda via e-Voting system.

**Resolution:** The Meeting considered and resolved to approve the election of the two retiring directors, i.e., Mr. Kirit Shah and Ms. Sameera Shah for another term, and to approve the appointment of Mr. Plakorn Wanglee as an independent director to replace Mr. Thor Santisiri who does not seek re-election, as proposed above in all respects, with the following results:

**Agenda Item No. 5.1 Re-appointment of Mr. Kirit Shah to be a Non-executive Director (if appointed he would be a Member of Remuneration Committee)**

Shareholders voting	Numbers of Votes	Accounting for percent
Approve	618,039,272	94.2815
Disapprove	37,486,030	5.7185
Voided	0	0.0000
Total (328 persons)	655,525,302	100.0000
Abstain	0	-

**Remark:** This agenda was to be approved by a majority of the shareholders who attend the meeting and cast their votes, excluding the abstained votes from the calculation base.

**Agenda Item No. 5.2 Re-appointment of Ms. Sameera Shah to be a Non-executive Director**

Shareholders voting	Numbers of Votes	Accounting for percent
Approve	649,979,211	99.1539
Disapprove	5,546,091	0.8461
Voided	0	0.0000
Total (328 persons)	655,525,302	100.0000
Abstain	0	-

**Remark:** This agenda was to be approved by a majority of the shareholders who attend the meeting and cast their votes, excluding the abstained votes from the calculation base.

**Agenda Item No. 5.3 Appointment of Mr. Plakorn Wanglee to be an Independent Director to replace Mr. Thor Santisiri who does not seek re-election**

Shareholders voting	Numbers of Votes	Accounting for percent
Approve	649,850,596	99.1343
Disapprove	5,674,606	0.8657
Voided	0	0.0000
Total (328 persons)	655,525,202	100.0000
Abstain	0	-

**Remark:** This agenda was to be approved by a majority of the shareholders who attend the meeting and cast their votes, excluding the abstained votes from the calculation base.

**Agenda Item No. 6 To consider and approve the determination of the directors' remuneration**

According to Section 90 of the PLCA and Article 22 of the Articles of Association of the Company, the directors shall be entitled to remuneration from the Company in the form of awards, meeting allowances, retirement pensions, bonuses or other benefits in other forms as approved by the shareholders meeting, by a vote of no less than two-thirds (2/3) of the number of the shareholders attending the meeting.

The MC informed the Meeting that the Remuneration Committee considered and determined the directors' remuneration by using the applicable criteria from the size of business and the responsibilities of the Board in comparison with other companies with the same range of revenue and market capitalization and listed on the Stock Exchange of Thailand. The Remuneration Committee deemed it appropriate to propose remuneration which shall be paid in accordance with the positions, roles, and responsibilities (without any other benefits) at the same rates as those applicable in 2025, which remuneration would be paid on a quarterly basis.

In this regard, the Board deemed appropriate to propose the Meeting to consider and approve the determination of directors' remuneration for 2026, which shall be paid in accordance with the positions, roles, and responsibilities (without any other benefits) at the same rates as were applicable in the prior year, as recommended by the Remuneration Committee as follows:

No.	Annual Remuneration Based on Position	2026 (Baht) (Proposed)	2025 (Baht)
1	Chairperson	1,620,675	1,620,675
2	Vice Chairperson	449,820	449,820
3	Independent Director who is Chair of sub-committee	277,830	277,830
4	Director or Independent Director	694,575	694,575
5	Independent Director who is member of one or more sub-committees	231,525	231,525

The remuneration would be paid to each director in quarterly instalments.

Based on the above, the annual remuneration to be paid to each director as per his/her position(s) would be as follows:

Name of Director	Annual Remuneration (Baht per Annum)			
	2026 (Proposed)	2025	2024	2023
Mr. Alan Kam <sup>(1.1)</sup>	2,315,250	1,653,750	1,653,750	1,575,000
Dr. Nithinart Sindhudeacha <sup>(1.2)</sup>	1,653,750	1,203,930	1,203,930	1,203,930
Mr. Vijay Karwal <sup>(1.3)</sup>	1,203,930	1,203,930	1,203,930	1,146,600
Mr. Thor Santisiri	- (not re-elected)	1,203,930	1,203,930	1,146,600
Mr. Kirit Shah	694,575	694,575	694,575	661,500
Mr. Ishaan Shah	694,575	694,575	661,500	661,500
Ms. Sameera Shah	694,575	694,575	694,575	661,500
Mr. Shiraz Erach Poonevala	694,575	694,575	694,575	661,500
Mr. Vivek Dhawan	Declined to receive remuneration			
Mr. Thomas Abraham	Declined to receive remuneration			
Mr. Ramachandran Rajamanickam <sup>(1.4)</sup>	1,203,930	-	-	-
Mr. Plakom Wanglee <sup>(1.5)</sup>	1,203,930	-	-	-
Mr. Meechai Viravaidya <sup>(1.6)</sup>	2,315,250	2,315,250	2,315,250	2,205,000
The Company does not grant any benefits to directors other than the above annual remuneration.				

**Remark:** (1) According to the resolution of the Board of Directors' Meeting No. 2/2026 held on February 24, 2026, the Board resolved to appoint the new Chairperson and Vice Chairperson and approve the restructuring of sub-committees, with details as follows:

- (1.1) The appointment of Mr. Alan Kam as Chairperson of the Board, in place of Mr. Meechai Viravaidya, from his former position as Vice Chairman of the Board, with effect from February 25, 2026 onwards. His remuneration shall be adjusted in accordance with his new positions, roles, and responsibilities.
- (1.2) The appointment of Dr. Nithinart Sindhudeacha as Vice Chair of the Board, in place of Mr. Alan Kam, with effect from February 25, 2026 onwards. Her remuneration shall be adjusted in accordance with her new positions, roles, and responsibilities.
- (1.3) The appointment of Mr. Vijay Karwal as a member of the Nomination Committee and Chairman of the Audit Committee, with effect from April 3, 2026 onwards.
- (1.4) The appointment of Mr. Ramachandran Rajamanickam as an Independent Director, effective from February 25, 2026 onwards, and in further roles as Chair of Remuneration

Committee and member of Audit Committee, effective from April 3, 2026 onwards.

(1.5) If Mr. Plakom Wanglee was appointed as Independent Director by the Annual General Meeting of Shareholders on April 3, 2026 pursuant to Agenda Item No. 5 above to replace Mr. Thor Santisiri, Mr. Plakom Wanglee would also be Chair of Nomination Committee and member of Audit Committee of the Company by virtue of the resolution of the Board of Directors' Meeting of the Company No. 2/2026 on February 24, 2026, with effect from April 3, 2026 onwards. His remuneration shall be paid in accordance with his positions, roles, and responsibilities.

(1.6) The Company would pay the remuneration to the Meechai Pattana School toward scholarships on behalf of Mr. Meechai Viravaidya, with payment made up to the last day on which he held office, and with his resignation taking effect on February 24, 2026.

(1.7) The re-structuring of the sub-committees shall be as follows:

Sub-committees	Present	Proposed and approved	Effective date
Audit Committee	1. Mr. Alan Kam 2. Mr. Vijay Karwal 3. Mr. Thor Santhisiri	1. Mr. Vijay Karwal (Chair) 2. Mr. Plakom Wanglee 3. Mr. Ramachandran Rajamanickam	April 3, 2026
Nomination Committee	1. Mr. Vijay Karwal 2. Mr. Alan Kam 3. Dr. Nithinart Sinthudeacha	1. Mr. Plakom Wanglee (Chair) 2. Mr. Vijay Karwal 3. Dr. Nithinart Sinthudeacha	April 3, 2026
Remuneration Committee	1. Mr. Thor Santhisiri 2. Mr. Kirit C. Shah 3. Mr. Vivek Dhawan	1. Mr. Ramachandran Rajamanickam (Chair) 2. Mr. Kirit C. Shah 3. Mr. Vivek Dhawan	April 3, 2026
Sustainability, Risk Management and Corporate Governance Committee	1. Dr. Nithinart Sinthudeacha 2. Mr. Vivek Dhawan 3. Mr. Thomas Abraham	1. Dr. Nithinart Sinthudeacha (Chair) 2. Mr. Vivek Dhawan 3. Mr. Thomas Abraham	April 3, 2026

Further, the MC provided an opportunity for the Meeting to express any opinion and enquire any queries in relation to this agenda. However, there were no opinions provided or queries asked. The MC then asked the Meeting to consider and approve the determination of the directors' remuneration, as proposed above, and cast the votes in this agenda, via e-Voting system.

**Resolution:** The Meeting considered and resolved to approve the determination of the directors' remuneration, as proposed above in all respects, with the following results:

Shareholders voting	Numbers of Votes	Accounting for percent
Approve	655,524,823	99.9999
Disapprove	0	0.0000
Abstain	479	0.0001
Voided	0	0.0000
Total (328 persons)	655,525,302	100.0000

**Remark:** This agenda was to be approved by a vote of not less than two-thirds of the shareholders who attend the meeting, including the abstained votes in the calculation base.

**Agenda Item No. 7**

**To consider and approve the appointment of auditors from KPMG Phoomchai Audit Ltd. and determination of the audit fee of the Company for the year ended December 31, 2026**

Under Section 120 of the PLCA and Article 36 (6) of the Articles of Association of the Company, the Annual General Meeting of Shareholders shall appoint the auditors and determine the audit fee of the Company in each year. In appointing the auditor, the former auditor may be re-appointed.

The MC informed the Meeting that the Audit Committee had considered the qualifications of four auditors in terms of their performance and independence as well as the remuneration, and expressed their opinions to the Board to propose the appointment of Ms. Sureerat Thongarunsang, CPA Registration No. 4409, or Ms. Vilaivan Pholprasert, CPA Registration No. 8420, or Mr. Chokechai Ngamwutikul, CPA Registration No. 9728, or Mr. Sumate Jangsamsee, CPA Registration No. 9362 from KPMG Phoomchai Audit Ltd. as the auditor of the Company for the year 2026. The Audit Committee also proposed that the 2026 audit fee should be amounted to Baht 5.42 million, and other expenses as per actual but not exceeding 5% of the audit fee.

In this regard, the Board deemed appropriate to propose the Meeting to consider and approve the appointment of auditors and determination of the audit fee of the Company for the year ended December 31, 2026, as reviewed and recommended by the Audit Committee, and approved by the Board, and one of the following auditors may audit and provide opinions on the Company financial statements for the year ended December 31, 2026:

No.	Name of Auditor	CPA Registration Number	Number of Years Signed Financial Statements / Number of Years of Being Auditor of the Company
1	Ms. Sureerat Thongarunsang	4409	4 / 7 Years
2	Ms. Vilaivan Pholprasert	8420	- / 7 Years
3	Mr. Chokechai Ngamwutikul	9728	- / 7 Years
4	Mr. Sumate Jangsamsee	9362	- / 7 Years

In the case where the aforementioned auditors were unable to perform their duties, KPMG Phoomchai Audit Ltd. shall be authorized to appoint any of the firm's qualified auditors to audit and give opinion to the financial statements of the Company.

In this respect, none of the proposed auditors had given opinion on the Company's financial statements for more than seven years. Therefore, all of the proposed auditors possessed the qualifications as required by the Notification of Capital Market Supervisory Board No. Tor Jor. 44/2556 re: Rules, Conditions and Procedures for Disclosure of Information Relating to the Financial Status and Operating Results of the Company issuing the Securities (as amended).

None of the auditors whose names were proposed had any relationship with nor interest in the Company, subsidiaries, management, major shareholders or the related persons of such persons and, therefore, they were independent to audit and give opinion on the Company's financial statements.

The proposed auditors would also audit all subsidiaries of the Company in Thailand.

The Board also deemed appropriate to propose that the Meeting consider and approve the remuneration for 2026 quarterly reviews and annual audit which was illustrated in the table below:

Type of Fees	Year				
	2026 (Million Baht) (Proposed)	2025 (Million Baht)	2024 (Million Baht)	2023 (Million Baht)	2022 (Million Baht)
<b>The Company (for approval)</b>					
1. Audit Fee					
- Annual audit fee and quarterly review fee	5.42	5.31	5.07	4.96	4.68
- Increase (%)	2.2	4.6	2.2	6.0	-
- One-time fee for review of acquisitions	-	-	-	-	-
<b>Total Audit Fee</b>	<b>5.42</b>	<b>5.31</b>	<b>5.07</b>	<b>4.96</b>	<b>4.68</b>
2. Non-Audit Fee (for information)	3.11	12.34	0.92	0.92	0.98
- BOI audit	-	0.10	0.10	0.10	0.10
- Transfer pricing	0.60	0.60	0.82	0.82	0.88
- Information technology consultant	2.5	11.6	-	-	-
<b>Subsidiary (for information)</b>					
1. Audit Fee					
- Annual audit fee and quarterly review fee	6.12	6.00	5.90	5.79	5.57
- Increase (%)	1.9	1.7	2.0	4.0	-
2. Non-Audit Fee	-	-	-	-	-
<b>Grand Total</b>	<b>14.65</b>	<b>23.65</b>	<b>11.89</b>	<b>11.67</b>	<b>11.22</b>
<b>Audit Fee</b>	<b>11.54</b>	<b>11.31</b>	<b>10.97</b>	<b>10.75</b>	<b>10.25</b>
<b>Non-Audit Fee</b>	<b>3.11</b>	<b>12.34</b>	<b>0.92</b>	<b>0.92</b>	<b>0.98</b>

Further, the MC provided an opportunity for the Meeting to enquire any queries in relation to this agenda. However, there were no opinions provided or queries asked. The MC then asked the Meeting to consider and approve the appointment of the auditors from KPMG Phoomchai Audit Ltd. and determination of the audit fee of the Company for the year ended December 31, 2026, as proposed above, and cast the votes in this agenda, via e-Voting system.

**Resolution:** The Meeting considered and resolved to approve the appointment of auditors from KPMG Phoomchai Audit Ltd. and determination of the audit fee of the Company for the year ended December 31, 2026 as proposed in all respects, with the following results:

Shareholders voting	Numbers of Votes	Accounting for percent
Approve	591,097,363	90.4704
Disapprove	62,262,839	9.5296
Voided	0	0.0000
Total (328 persons)	653,360,202	100.0000
Abstain	2,165,100	-

**Remark:** This agenda was to be approved by a majority of the shareholders who attend the meeting and cast their votes, excluding the abstained votes from the calculation base.

**Q&A Session**

The MC opened the floor to questions and opinions from the shareholders. The shareholders' questions and management's responses can be summarized as follows:

**Opinion/ Query/ Response:**

**Mr. Anukul Piyathananukul**, a shareholder attending the Meeting in person, inquired through the question submission channel on the impairment cost of the two subsidiaries at the rate of 100% as to whether such cost would continue to exist in the next year and following years.

**Ms. Sujintana** clarified that such impairment cost would no longer exist in the next year and following years.


**Mr. Anukul Piyathananukul**, a shareholder attending the Meeting in person, inquired through the question submission channel on the effect of the increase of price of petrochemical products (as a result of warfare situation in the middle east) as to whether it affected the Company's product cost or API, and inquired on the Company's plan to mitigate such risk in the aspect of both costs and raw materials required for manufacturing of the Company's products per this year's plan.


**Mr. Vivek** clarified that the increase of price of petrochemical products has not significantly impacted the Company's raw material cost, given that most of the Company's products were not petrochemical products. However, certain costs such as gasoline and electricity would likely be higher. Nevertheless, the Company did not see the need to increase the prices of its products to be sold within the next three to six months. The Company had gross margin at approximately 63 – 64% with the cost at roughly 30%, which comprised raw material cost of not over 15 – 20%. In respect of long-term consequence, the Company would continue to monitor the situation and prepare contingency plan.

There was no shareholder proposing other matters for the consideration of the Meeting or having additional questions. Mr. Alan Kam then thanked the meeting attendants, and declared the Meeting adjourned at 3.37 p.m.

**Mega Lifesciences Public Company Limited**



  
\_\_\_\_\_  
(Mr. Vivek Dhawan)  
Chief Executive Officer and Chief Coach

  
\_\_\_\_\_  
(Mr. Thomas Abraham)  
Chief Financial Officer